PTC Therapeutics, Inc.

South Plainfield, NJ 07080

Market Performance

NASDAQ: PTCT
Market Cap $776 Million
52 Week High $4.03
52 Week Low $22.00

SBIR Award Summary

Total Number of Awards 16
Total Value of Awards $5.3MM
First Award Date 09/01/00
Most Recent Award Date 05/20/07

Key Personnel

Last Name Name Awards Contact
Dougherty Joseph Dougherty 3
Rando Robert Rando 1
Jacobson Allan S. Jacobson 3
Trotta Christopher Robert Trotta 1
Gu Zhengxian Gu 3
Colacino Joseph M Colacino 3
Welch Ellen M Welch 1
Trifillis Panayiota Trifillis 1

16 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/20/07 - 05/19/08

DESCRIPTION (provided by applicant): Nonsense mutations inactivate gene function by promoting synthesis of truncated polypeptides and accelerating mRNA decay. These mutations are a significant cause of genetic disorders, giving rise to 15- 30% of all disease-causing alleles. Recent studies have shown that the antibiotic, gentamicin, can suppress...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/18/06 - 08/31/07

DESCRIPTION (provided by applicant): Up-regulation of vascular endothelial growth factor (VEGF), a key factor for angiogenesis, is an important contributor to the pathogenesis of cancer. The abundance of VEGF is in large part controlled at the posttranscriptional levels by sequences in both the 5'- and 3'-untranslated regions (UTRs) of its mRNA....

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/20/06 - 05/19/07

DESCRIPTION (provided by applicant): Nonsense mutations inactivate gene function by promoting synthesis of truncated polypeptides and accelerating mRNA decay. These mutations are a significant cause of genetic disorders, giving rise to 15- 30% of all disease-causing alleles. Recent studies have shown that the antibiotic, gentamicin, can suppress...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/21/05 - 08/31/06

DESCRIPTION (provided by applicant): Up-regulation of vascular endothelial growth factor (VEGF), a key factor for angiogenesis, is an important contributor to the pathogenesis of cancer. The abundance of VEGF is in large part controlled at the posttranscriptional levels by sequences in both the 5'- and 3'-untranslated regions (UTRs) of its mRNA....

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/05 - 02/28/06

DESCRIPTION (provided by applicant): It is estimated that over 170 million people are infected by hepatitis C virus (HCV) worldwide. Currently, there are limited therapeutic agents and no vaccine available for HCV infection. Thus, it is necessary to develop new anti-HCV drugs. HCV is a member of the family Flaviviridae. The HCV genome contains ...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/23/04 - 03/22/05

DESCRIPTION (provided by applicant): Nonsense mutations inactivate gene function by promoting synthesis of truncated polypeptides and accelerating mRNA decay. These mutations are a significant cause of genetic disorders, giving rise to 15- 30% of all disease-causing alleles. Recent studies have shown that the antibiotic, gentamicin, can suppress...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 03/31/06

DESCRIPTION (provided by applicant): Highly active antiretroviral therapy (HAART) has had a great impact upon reducing AIDS related morbidity and mortality. However, due to the high degree of HIV-1 variation, novel strains resistant to the present HAART cocktail of drugs have arisen. Coupled with the considerable toxicity associated with HAAR...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 09/30/04

DESCRIPTION (provided by applicant): Up-regulation of vascular endothelial growth factor (VEGF), a key factor for angiogenesis, is an important contributor to the pathogenesis of cancers, diabetic retinopathy, and exudative macular degeneration. The abundance of VEGF is in large part controlled at the post-transcriptional level by sequences i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/04 - 02/28/05

DESCRIPTION (provided by applicant): It is estimated that over 170 million people are infected by hepatitis C virus (HCV) worldwide. Currently, there are limited therapeutic agents and no vaccine available for HCV infection. Thus, it is necessary to develop new anti-HCV drugs. HCV is a member of the family Flaviviridae. The HCV genome contains ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 09/29/04

DESCRIPTION (provided by applicant): Both the emergence of multidrug resistant bacteria and the further development and deployment of bioterrorism agents emphasizes the urgency for identifying novel antibiotics. PTC Therapeutics, Inc. is a company dedicated to targeting post-transcriptional cellular pathways by identifying small molecule compo...

Load More